v3.25.4
INCOME TAXES - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Valuation Allowance [Line Items]      
Nondeductible R&D charges $ 290 $ 2,538 $ 0
State and local taxes (net of valuation allowance) 0.50% 0.30% 1.10%
Effective income tax rate reconciliation, GILTI net of foreign derived intangible income deduction     $ 325
Effective income tax rate reconciliation, foreign income tax rate differential, effect on net operating loss carryforwards, amount     123
Effective income tax rate reconciliation, deduction, impairment of subsidiary investments   $ 0 656
Effective income tax rate reconciliation, valuation allowance cost (reversal), unrealized equity investment loss     193
Effective income tax rate reconciliation, tax settlement, amount   644 89
Valuation allowance $ 960 929  
Income tax payments 3,264 3,900 4,300
Transition taxes paid 991 799 $ 567
Transition tax due 2025 244    
Orbital Therapeutics      
Valuation Allowance [Line Items]      
Nondeductible R&D charges 290    
Effective income tax rate reconciliation, nondeductible expense, amount 1,400    
Karuna      
Valuation Allowance [Line Items]      
Effective income tax rate reconciliation, nondeductible expense, amount   $ 12,100  
Foreign Net Operating Loss and Tax Credit Carryforwards      
Valuation Allowance [Line Items]      
Valuation allowance 163    
State Net Operating Loss and Tax Credit Carryforwards      
Valuation Allowance [Line Items]      
Valuation allowance 527    
SEC Schedule, 12-09, Valuation Allowance, Other Tax Carryforward      
Valuation Allowance [Line Items]      
Valuation allowance 270    
Domestic Tax Jurisdiction      
Valuation Allowance [Line Items]      
Operating loss carryforwards $ 1,300